FISHER + PAYKEL HEALTH.
Research FISHER + PAYKEL HEALTH. (FPLB) on Bullrun: valuation model: 29.2% overvalued, market cap EUR 11.10B, P/E 47.3, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFPLB
- ExchangeF
- CountryNew Zealand
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Valuation signal29.2% overvalued
- Market capEUR 11.10B
- P/E47.3
- Dividend yield1.4%
- Financial periodQ1 2025
- RevenueEUR 1.28B
- Net incomeEUR 377.20M
- Free cash flowEUR 445.60M
- Gross margin41.4%
Valuation Snapshot
Bullrun's latest valuation model marks FISHER + PAYKEL HEALTH. as 29.2% overvalued; latest market cap is EUR 11.10B; P/E is 47.3; dividend yield is 1.4%.
About FISHER + PAYKEL HEALTH.
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital.
Frequently asked questions
Is FISHER + PAYKEL HEALTH. overvalued or undervalued?
Bullrun's valuation model currently marks FISHER + PAYKEL HEALTH. as 29.2% overvalued.
What is FISHER + PAYKEL HEALTH.'s market cap?
FISHER + PAYKEL HEALTH.'s market capitalization is EUR 11.10B.
What is FISHER + PAYKEL HEALTH.'s P/E ratio?
FISHER + PAYKEL HEALTH.'s price-to-earnings (P/E) ratio is 47.3.
Does FISHER + PAYKEL HEALTH. pay a dividend?
FISHER + PAYKEL HEALTH. has a dividend yield of 1.4%.
What does FISHER + PAYKEL HEALTH. do?
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally.